All In Biotech

Drug Trial Radar · NCT05408663

A Phase 1 Study of EXT608 in Healthy Adults

EXT608 in Human Healthy Adults; A First-in-Human, Randomized, Double-Blind, Placebo-controlled, Single Dose Escalation Study

Last checked: Nov 19, 2026Latest source record: Feb 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Jul 21, 2022

Primary completion

Jun 13, 2023

Study completion Jun 13, 2023

Sponsor

Lead sponsor
Extend Biosciences Inc.Industry
Sponsor type
Industry
Collaborators
Integrated Medical Development; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Pharmaceutical Research Associates
First posted
Jun 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose safety and tolerability study of EXT608 in healthy subjects. There will be up to 6 sequential dose escalation cohorts of 4 participants. In each cohort 3 participants will receive EXT608 and 1 participant will receive placebo.

Conditions

  • Safety Issues

Interventions

  • EXT608Drug

    EXT608 is an investigational drug administered via subcutaneous injection

  • PlaceboOther

    matching placebo administered via subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Characterize the Safety and Tolerability of EXT608Time frame: Day 0 to Day 28
  2. Characterize the Safety and Tolerability of EXT608Time frame: Day 0 - Day 28
  3. Characterize the Safety and Tolerability of EXT608Time frame: Day 0 - Day 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PRA

    Lenexa, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.